<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94207">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063555</url>
  </required_header>
  <id_info>
    <org_study_id>DAR-901-MDES</org_study_id>
    <nct_id>NCT02063555</nct_id>
  </id_info>
  <brief_title>Phase I Trial of DAR-901</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Dartmouth Committee for the Protection of Human Subjects</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study
      of DAR 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in HIV
      negative and HIV positive adults previously vaccinated with BCG. The goals of the trial are
      to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine
      at different dose levels, ranging from 0.1 to 1 mg.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects will be followed for both systemic side effects and injection site reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>10 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cellular and humoral responses to the vaccine antigen will be tested at baseline and after each of 3 doses of vaccine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">77</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>DAR-901</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal administration at 0, 2 and 4 months
Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DAR-901</intervention_name>
    <arm_group_label>DAR-901</arm_group_label>
    <other_name>Inactivated Mycobacterium obuense</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <arm_group_label>BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sterile saline</intervention_name>
    <arm_group_label>Sterile saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects: age 18-65, prior BCG vaccine (scar)

        56 HIV negative subjects: negative ELISA for HIV (48 subjects with negative IGRA, 8
        subjects with positive IGRA)

        21 HIV positive subjects: positive ELISA for HIV, on ART (13 subjects with negative IGRA,
        8 subjects with positive IGRA)

        Exclusion Criteria: pregnancy, positive serology for hepatitis B or C, active tuberculosis
        immunosuppression, severe medical illness

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles F. von Reyn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisel School of Medicine at Dartmouth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles F. von Reyn, MD</last_name>
    <phone>603 650 7167</phone>
    <email>fvr@dartmouth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy Lahey, MD</last_name>
    <phone>603 650 8840</phone>
    <email>timothy.lahey@dartmouth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Haynes, RN</last_name>
      <phone>603-650-5250</phone>
      <email>brenda.haynes@hitchcock.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>BCG</keyword>
  <keyword>HIV</keyword>
  <keyword>TB Vaccines</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
